Table 3. Main oral and injectable contraceptives (> 0.5% prevalence) used by women of childbearing age. PNAUM, Brazil, 2014.
| Main contraceptives | %a | 95%CIa |
|---|---|---|
| Monophasic combined oral | 71.6 | 68.9–74.1 |
| Levonorgestrel + ethinyl estradiol (low level)b,c | 38.7 | 35.3–42.1 |
| Cyproterone + ethinyl estradiol (low level)b | 9.2 | 7.8–10.8 |
| Gestodene + ethinyl estradiol (low level)b | 8.1 | 6.8–9.7 |
| Drospirenone + ethinyl estradiol (level)b | 5.8 | 4.4–7.5 |
| Levonorgestrel + ethinyl estradiol (medium or high level)b | 3.5 | 2.7–4.5 |
| Gestodene + ethinyl estradiol (ultralow level)b | 3.2 | 2.2–4.6 |
| Desogestrel + ethinyl estradiol (low level)b | 2.6 | 1.9–3.7 |
| Bi- or triphasic combined oral | 3.2 | 2.4–4.3 |
| Ethinylestradiol + levonorgestrel | 1.9 | 1.3–2.8 |
| Estradiol valerate + dienogest | 0.8 | 0.4–1.7 |
| Oral with isolated progestogen | 5.0 | 3.9–6.4 |
| Desogestrel | 3.3 | 2.4–4.6 |
| Norethisterone acetatec | 1.6 | 1.1–2.3 |
| Injectable | 12.6 | 10.7–14.8 |
| Norethisterone enanthate + valerate estradiolc | 4.4 | 3.4–5.7 |
| Medroxyprogesterone acetatec | 2.9 | 2.1–4.0 |
| Non-identified | 7.6 | 6.2–9.5 |
a Percentages weighted by the sampling weights (sample not self-weighted).
b ultralow (≤ 0.015 mg of estrogen); low (0.035, 0.03, 0.02 mg of estrogen) and medium and high (≥ 0.05 mg of estrogen).
c Contraceptives listed in Relação Nacional de Medicamentos Essenciais (RENAME – National List of Essential Medicines) and available at Popular Pharmacy Program.